Persetujuan terapi T-Cell CAR sareng kasadiaan

Juli 2021: Dina Juni 2014, KITE Biotéhnologi Company, kalawan ngan 19 pagawé, didaptarkeun dina NASDAQ di Amérika Serikat, sarta nyandak 130 juta dollar AS dina hiji poé! Ngan dua bulan ti harita, Juno Biotéhnologi ngagaduhan kirang ti 20 pagawé Pausahaan ngumumkeun yén éta parantos suksés ngangkat 130 juta dolar AS dina hiji lump sum, ku kituna Juno parantos ngumpulkeun langkung ti 300 juta dina sataun! Dua pausahaan leutik ieu teu boga panghasilan jeung teu aya ubar didaptarkeun, jadi naha maranéhanana jadi populer jeung investor jeung boga duit dikirim ka maranehna? Kusabab aranjeunna parantos ngawasa téknologi anu disebut terapi sél CAR-T, téknologi anu tiasa ngubaran kanker! Kiwari, CAR-T anu kasohor disebatkeun, ampir sadayana terang ieu, Immunotherapy parantos sacara resmi ngalebetkeun aplikasi klinis.

FDA parantos nyatujuan dua terapi CAR-T

Currently, two CAR T-cell therapies approved by the FDA, Yescarta and Kymriah, are used to treat leukemia and lymphomaMasing-masing.

Perlakuan ieu kabuktosan nyababkeun réspon anu signifikan-bahkan penderita kanker anu maju anu salamet ngan ukur sababaraha bulan tiasa dibasmi sadayana, sareng dina sababaraha kasus ngaréspon pisan sababaraha bulan atanapi bahkan taun.

Salaku conto, Emily, mojang leukemia, parantos hasil diubaran ku terapi sél CAR-T salami 7 taun. Anjeunna ogé parantos janten juru bicara pikeun terapi epik ieu sareng parantos kacatet dina sajarah.

Kaajaiban terapi T-Cell CAR

EMILY - LEUKEMIA GIRL 2019

Dr CARL June - pamekar mobil T-sél terapi

Naon terapi T CAR T?

Terapi ieu ngasingkeun sél T imun ti pasién, sareng sacara genétis insinyur sél ieu dina vitro, dimuat ku "reséptor antigen chimeric" (CAR) anu mikawanoh antigen permukaan sél kanker. Salajengna, sél anu dirobih ieu ngalaman ékspansi anu éksténsif di laboratorium sateuacan diinfus deui ka pasién. Di dinya, aranjeunna siga tentara terlatih anu dilengkepan ku senjata pangénggalna pikeun ngaluncurkeun serangan anu teu kendat dina sél kanker.

Botol téknologi CAR-T dina tumor padet

However, the reason why it is effective in hematoma is because the tumor cells of hematoma have an ancestral target-CD19 (only stored in tumor cells but not in normal cells), we can easily rely on this target Lead CAR-T cells to find cancer cells and eliminate cancer. A third CAR T-cell therapy targeting an antigen called BCMA is expected to be approved for sababaraha myeloma (Bluebird) later this year. But there are not so obvious targets in solid tumors that exist only in cancer cells and not in normal cells.

Kusabab kitu, sél CAR-T henteu acan épéktip klinis pikeun ngubaran tumor padet. Komunitas médis salawasna ngarepkeun yén sél CAR T tiasa ngembangkeun target khusus énggal pikeun tumor anu langkung padet.

Terobosan dina terapi CAR-T ngalawan tumor padet

At present, with the change of CAR-T algebra, CAR-T has obvious improvements in proliferation and cytokine release. This technology has finally broken the ice, and more and more clinical trials have begun to try to use CAR-T for solid tumors. Treatment, patients with advanced solid tumors ushered in a warm spring!

Target antigen anu khas diantarana:

Mesothelin, used to treat mesothelioma, pancreatic cancer, ovarian cancer, lung cancer; CEA, used to treat lung cancer, colon cancer, stomach cancer, breast cancer and pancreatic cancer; MUC-1, used to treat liver cancer, lung cancer , Pancreatic cancer, colon cancer, gastric cancer; GPC3, for the treatment of liver cancer; EGFRvII, for the treatment of gliomas, head and neck tumors; B7-H3, for the treatment of Ewing’s sarcoma, rhabdomyosarcoma, nephroblastoma, nerves Blastoma and medulloblastoma and brain stem tumors (DIPG), which are particularly difficult to treat;

PSMA, used for kanker prostat, jsb.

Claudin 18.2, used for gastric cancer, kanker pancreaticJeung sajabana

01 Mesothelin CAR-T

Mesothelin is a cell surface glycoprotein that is highly expressed in various tumors, such as malignant pleural mesothelioma, pancreatic cancer, kanker indung and some lung cancers, and is lowly expressed on the surface of normal pleura, peritoneum and pericardium. CAR-T cells against mesothelin have potential antitumor effects.

The latest results of mesothelin CAR-T therapy published by the University of Pennsylvania at the American Society of Clinical Oncology in 2019 show that a total of 6 patients with refractory metastatic pancreatic duct adénokarsinoma were successfully enrolled, and all patients have received 2 or more Multiple treatments. These patients were infused with mesothelin CAR T cells 3 times a week for a total of 9 doses. The results showed that there were 2 patients with stable disease, and their progression-free survival time was 3.8 months and 5.4 months.

Ku alatan éta, terapi novél ieu sacara biologis aktip di penderita kanker pankreas, sareng studi ieu masih dina uji klinis (NCT03323944).

02 - B7-H3 "Pan kanker" CAR-T

Tim Profesor Majzner ti Stanford Medical College parantos ngembangkeun terapi CAR-T generasi anyar pikeun tumor padet. Ieu husus Terapi T-Cell mobil dipuji salaku salah sahiji terapi anu paling ngajangjikeun sabab nargétkeun B7-H3, tingkat luhur antigen anu aya dina seueur tumor padet, kalebet sababaraha kanker budak leutik.

They screened 388 children’s tumors for testing. The results showed that B7-H3 was present in 84% of the samples (tumor cells). B7-H3 content was very high in 70% of the samples. These include Ewing’s sarcoma, rhabdomyosarcoma, nephroblastoma, neuroblastoma and medulloblastoma, as well as brain stem tumors (DIPG) that are particularly difficult to treat.

Salajengna, Profesor Majzner sareng timnya ngawangun generasi sél CAR-T-B7-H3 CAR-T anyar ngalangkungan téknologi éditan gén.

Langsung saatos, panaliti henteu sabar ngantosan ngamimitian percobaan dina beurit. Aranjeunna mindahkeun sél tumor manusa kana beurit pikeun ngabentuk sababaraha modél beurit kanker budak leutik. Modél beurit ieu dibéré B7-H3 Terapi T-Cell mobil sareng kelompok kontrol CD-19 CAR-T, masing-masing.

Saréréa reuwas! Profesor Majzner nyarios: "Tumorna nembé ngaleungit."

03, claudin18.2 CAR-T

Dina dua taun ka pengker, tumor padet di nagara urang parantos ngahontal prestasi anu kasohor di dunya, sareng tumor solid munggaran di dunya Terapi CAR-T nargétkeun Claudin 18.2 parantos dikembangkeun.

Claudin18.2 (CLDN18.2) nyaéta protéin mémbran gastric-spésifik sareng dianggap udagan terapi poténsial pikeun kanker lambung sareng jinis kanker anu sanés. Dumasar ieu, panalungtik Cina ngembangkeun sél CAR-T munggaran di dunya ngalawan Claudin 18.2.

Dina Konperénsi Tahunan ASCO 2019, pembaruan data klinis sél CAR-Claudin 18.2 T pikeun kanker lambung / pankreas nunjukkeun yén sél claudin 18.2 sél T CAR digunakeun pikeun ngubaran 12 kasus adénokarsinoma metastatik (7 kasus kanker lambung sareng 5 kasus pankreas kanker). Kajadian ngarugikeun serius, maot anu aya hubunganana sareng pangubaran, atanapi neurotoksisitas parah kajantenan.

Diantara 11 objék évaluasi:

1 kasus (adenocarcinoma lambung) lengkep lega;

3 kasus (adénokarsinoma lambung

2 kasus adenocarcinoma pankreas, 1 kasus) remisi parsial;

5 kasus éta stabil;

2 kasus maju;

Rata-rata tingkat réspon objektif nyaéta 33.3%.

Sumawona, sél CAR-Claudin 18.2 T pikeun panilitian préklinikal ngeunaan kanker lambung nunjukkeun yén sél CAR-T anu ditujukeun ka Claudin 18.2 tiasa ngaleungitkeun lengkep tumor lambung dina modél beurit tanpa keracunan anu teu sasaran.

The good news is that this trial has been pioneered by the Department of Gastroenterology and Oncology at Peking University Cancer Hospital, which is famous for tumor beuteung in China, to evaluate autologous humanized anti-claudin 18.2 chimeric antigen receptor T cells in advanced solid tumors. Safety and efficacy. Entry criteria (partial)

1. Umur 18 dugi 75 taun, lalaki atanapi awéwé;

2. Subjék anu tumors dikonfirmasi sacara padet tumor (ie kanker lambung maju, kanker simpang esophagogastric, sareng kanker pankreas) anu gagal dina perlakuan standar;

3. Claudin 18.2 IHC pewarnaan positip;

4. Hirup anu diarepkeun> 12 minggu;

Terapi T-Cell mobil dina rekrutmen klinis

Salian kamajuan panalungtikan klinis terobosan di luhur, rumah sakit domestik utama ayeuna aktip ngalaksanakeun panalungtikan klinis CAR-T dina sababaraha tumor.

Syarat pasién: Umur 18-80 taun, diperkirakeun salamet sahenteuna 6 bulan (tina ulasan awal bahan dugi ka réngsé perlakuan peryogi 5-6 bulan), umumna dina kaayaan anu saé, tiasa hirup sorangan.

Prosés aplikasi pikeun rekrutmen CAT T-Cell

1. Tinjauan awal bahan: laporan patologi, data pamariksaan gambar dina sabulan, laporan fungsi ati sareng ginjal panganyarna, kasimpulan pelepasan panganyarna dikintunkeun ka Departemen Médis CancerFax;

2. Rundingan nyanghareupan: pasién nyalira nyangking sadaya bahan kasus ka rékrutasi rumah sakit rekrutmen rundingan (laporan kasus, kasimpulan debit, pilem laporan pencitraan);

3. Deteksi histokimia imuno: ngadeteksi antigén permukaan sél tumor EGFR, MUC1 sareng mesothelin, salah sahiji anu positip pisan (ekspresi tinggi) tiasa nerapkeun terapi CAR T-Cell.

Saméméh mecenghulna terapi sél, tumor padet, kaasup adenocarcinoma lambung canggih jeung kanker pankréas, biasana dirawat kalayan bedah jeung radiotherapy jeung kémoterapi. Insiden adenokarsinoma lambung nyababkeun 95% tina kaganasan lambung, sareng kanker pankréas mangrupikeun tumor ganas anu umum. Tumor kalayan gelar pangluhurna, waktu survival median jeung tingkat survival 5 taun jauh leuwih handap tina tumor lianna, katelah "raja kanker".

Nanging, kaseueuran pasien gaduh kambuh lokal atanapi metastasis saatos dioperasikeun. Salaku tambahan, jenis tumor ganas ieu henteu peka radioterapi sareng kémoterapi. Ku alatan éta, dumasar kana terapi standar ayeuna, pangaruh pangobatan henteu idéal, sareng ramalanana goréng pisan. Munculna imunoterapi bakal mawa langkung seueur harepan sareng kaajaiban salamet jangka panjang ka pasién anu langkung maju.

Kami yakin pisan yén saatos dilebetkeun sistem pangaturan imun sélulér anu sampurna, nagara bakal muka panto imunoterapi sélulér pikeun nguntungkeun langkung seueur penderita kanker, sareng imunoterapi sélér nagara urang ogé bakal aya di panggung internasional.

Anjeun panginten hoyong maca: Terapi T-Cell CAR di Cina

FAQ ngeunaan terapi T-Cell MOBIL

Naha Terapi sél Car-T sayogi? Kanker naon anu diubaran utamina

A CAR-T cell immunotherapy has been disatujuan by the US FDA for the treatment of leukemia and lymphoma. Nanging, pangobatan tumor padet henteu acan disatujuan sareng ayeuna aya dina uji klinis

Naha sél Car-T tiasa ngubaran kanker lambung?

jawaban CAR-T pikeun kanker lambung ayeuna ngalaman uji klinis dina Kangker Beijing. Pasén diperyogikeun nganggo bagian jaringan dina sataun ka grup eksperimen pikeun deteksi target khusus. Upami hasil tés positip, maka

Naha aya uji klinis sél Car-T pikeun kanker lambung?

A Aya uji klinis domestik CAR-T pikeun kanker lambung, anu dilaksanakeun di Rumah Sakit Kanker Universitas Peking. Pasén diperyogikeun ngagaduhan bagian jaringan patologis dina sataun pikeun panyaringan target khusus. Pasién anu didaptarkeun ayeuna

Naha pasién kanker ati tiasa ilubiung dina uji klinis CAR-T?

jawaban According to your main complaint; the clinical application of CAR-T immunotherapy for solid tumors of kanker haté is not approved. The principle of CAR-T is to extract immune cells, and then use in vitro culture

Daptar pikeun terapi T-Cell CAR

otista